Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Randy F Sweis

Showing results (51-60 of 57) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 57 results.
The Lancet. Oncology|June 18, 2021
Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 studyChung-Han Lee, Amishi Yogesh Shah, Drew Rasco, et al.
Cancer Research|October 15, 2025
A Roadmap for the Future of Systems Biology in Cancer ResearchH Steven Wiley, Carlos F Lopez, Andrei S Rodin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2022
Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II TrialValentina Boni, Mary J Fidler, Hendrik-Tobias Arkenau, et al.
Research Square|November 30, 2021
Severe COVID-19 infection is associated with aberrant cytokine production by infected lung epithelial cells rather than by systemic immune dysfunctionSherin J Rouhani, Jonathan A Trujillo, Athalia R Pyzer, et al.
The New England Journal of Medicine|September 16, 2024
Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial CarcinomaAndrea B Apolo, Karla V Ballman, Guru Sonpavde, et al.
Journal for Immunotherapy of Cancer|May 23, 2019
Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshopDavide Bedognetti, Michele Ceccarelli, Lorenzo Galluzzi, et al.
Journal for Immunotherapy of Cancer|July 6, 2019
Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshopDavide Bedognetti, Michele Ceccarelli, Lorenzo Galluzzi, et al.
Pageof 6

Showing results (51-60 of 57) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 57 results.
The Lancet. Oncology|June 18, 2021
Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 studyChung-Han Lee, Amishi Yogesh Shah, Drew Rasco, et al.
Cancer Research|October 15, 2025
A Roadmap for the Future of Systems Biology in Cancer ResearchH Steven Wiley, Carlos F Lopez, Andrei S Rodin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2022
Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II TrialValentina Boni, Mary J Fidler, Hendrik-Tobias Arkenau, et al.
Research Square|November 30, 2021
Severe COVID-19 infection is associated with aberrant cytokine production by infected lung epithelial cells rather than by systemic immune dysfunctionSherin J Rouhani, Jonathan A Trujillo, Athalia R Pyzer, et al.
The New England Journal of Medicine|September 16, 2024
Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial CarcinomaAndrea B Apolo, Karla V Ballman, Guru Sonpavde, et al.
Journal for Immunotherapy of Cancer|May 23, 2019
Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshopDavide Bedognetti, Michele Ceccarelli, Lorenzo Galluzzi, et al.
Journal for Immunotherapy of Cancer|July 6, 2019
Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshopDavide Bedognetti, Michele Ceccarelli, Lorenzo Galluzzi, et al.
Pageof 6